Anticoagulation Inhibits Tumor Cell-mediated Release of Platelet Angiogenic Proteins and Diminishes Platelet Angiogenic Response

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Sep 26

PMID 24065244

Citations 48

Authors

Elisabeth M Battinelli

Beth A Markens

Rajesh A Kulenthirarajan

Kellie R Machlus

Robert Flaumenhaft

Joseph E Italiano Jr

Affiliations

Soon will be listed here.

Abstract

Platelets are a reservoir for angiogenic proteins that are secreted in a differentially regulated process. Because of the propensity for clotting, patients with malignancy are often anticoagulated with heparin products, which paradoxically offer a survival benefit by an unknown mechanism. We hypothesized that antithrombotic agents alter the release of angiogenesis regulatory proteins from platelets. Our data revealed that platelets exposed to heparins released significantly decreased vascular endothelial growth factor (VEGF) in response to adenosine 5'-diphosphate or tumor cells (MCF-7 cells) and exhibited a decreased angiogenic potential. The releasate from these platelets contained decreased proangiogenic proteins. The novel anticoagulant fondaparinux (Xa inhibitor) demonstrated a similar impact on the platelet angiogenic potential. Because these anticoagulants decrease thrombin generation, we hypothesized that they disrupt signaling through the platelet protease-activated receptor 1 (PAR1) receptor. Addition of PAR1 antagonists to platelets decreased VEGF release and angiogenic potential. Exposure to a PAR1 agonist in the presence of anticoagulants rescued the angiogenic potential. In vivo studies demonstrated that platelets from anticoagulated patients had decreased VEGF release and angiogenic potential. Our data suggest that the mechanism by which antithrombotic agents increase survival and decrease metastasis in cancer patients is through attenuation of platelet angiogenic potential.

Citing Articles

Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention.

Contursi A, Tacconelli S, Di Berardino S, De Michele A, Patrignani P Front Pharmacol. 2025; 15:1520488.

PMID: 39764464 PMC: 11701038. DOI: 10.3389/fphar.2024.1520488.

Novel Products as Promising Therapeutic Agents for Angiogenesis Inhibition.

Sultana S, Sultana S, Najib Ullah S, Zafar A Curr Drug Deliv. 2024; 22(2):181-194.

PMID: 38204254 DOI: 10.2174/0115672018277869231217165048.

Selenium enhances photodynamic therapy of C-phycocyanin against lung cancer via dual regulation of cytotoxicity and antioxidant activity.

Shen J, Xia H, Zhou X, Zhang L, Gao Q, He K Acta Biochim Biophys Sin (Shanghai). 2023; 55(12):1925-1937.

PMID: 37994159 PMC: 10753371. DOI: 10.3724/abbs.2023159.

Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis.

Jing H, Wu X, Xiang M, Wang C, Novakovic V, Shi J Cancers (Basel). 2023; 15(7).

PMID: 37046617 PMC: 10093313. DOI: 10.3390/cancers15071957.

Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients.

Johns C, Yen A, Rahimi A, Liu Y, Leitch A, Spangler A J Breast Cancer. 2023; 26(1):14-24.

PMID: 36762783 PMC: 9981985. DOI: 10.4048/jbc.2023.26.e3.

References

Bambace N, Levis J, Holmes C . The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets. 2010; 21(2):85-93. DOI: 10.3109/09537100903470298. View

Lee A, Rogers L, Longcroft J, Jeffery R . Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid. Clin Exp Metastasis. 1990; 8(2):165-71. DOI: 10.1007/BF00117789. View

Marchetti M, Diani E, Ten Cate H, Falanga A . Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica. 2012; 97(8):1173-80. PMC: 3409814. DOI: 10.3324/haematol.2011.055343. View

Gay L, Felding-Habermann B . Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11(2):123-34. PMC: 6894505. DOI: 10.1038/nrc3004. View

Boukerche H, Berthier-Vergnes O, Penin F, Tabone E, Lizard G, Bailly M . Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. Br J Haematol. 1994; 87(4):763-72. DOI: 10.1111/j.1365-2141.1994.tb06736.x. View

Jurasz P, Chung A, Radomski A, Radomski M . Nonremodeling properties of matrix metalloproteinases: the platelet connection. Circ Res. 2002; 90(10):1041-3. DOI: 10.1161/01.res.0000021398.28936.1d. View

Lapierre F, Holme K, Lam L, Tressler R, Storm N, Wee J . Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology. 1996; 6(3):355-66. DOI: 10.1093/glycob/6.3.355. View

Italiano Jr J, Richardson J, Patel-Hett S, Battinelli E, Zaslavsky A, Short S . Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2007; 111(3):1227-33. PMC: 2214735. DOI: 10.1182/blood-2007-09-113837. View

Gisterek I, Matkowski R, Lacko A, Sedlaczek P, Szewczyk K, Biecek P . Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res. 2009; 16(3):337-44. DOI: 10.1007/s12253-009-9211-8. View

10.

Demers M, Ho-Tin-Noe B, Schatzberg D, Yang J, Wagner D . Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011; 71(5):1540-9. PMC: 3078642. DOI: 10.1158/0008-5472.CAN-10-2038. View

11.

Nijziel M, van Oerle R, Hillen H, Hamulyak K . From Trousseau to angiogenesis: the link between the haemostatic system and cancer. Neth J Med. 2006; 64(11):403-10. View

12.

Suppiah R, Shaheen P, Elson P, Misbah S, Wood L, Motzer R . Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006; 107(8):1793-800. DOI: 10.1002/cncr.22237. View

13.

Camerer E, Qazi A, Duong D, Cornelissen I, Advincula R, Coughlin S . Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004; 104(2):397-401. DOI: 10.1182/blood-2004-02-0434. View

14.

Ludwig R, Boehme B, Podda M, Henschler R, Jager E, Tandi C . Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004; 64(8):2743-50. DOI: 10.1158/0008-5472.can-03-1054. View

15.

Kakkar A, Levine M, Kadziola Z, Lemoine N, Low V, Patel H . Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004; 22(10):1944-8. DOI: 10.1200/JCO.2004.10.002. View

16.

Badr Eslam R, Reiter N, Kaider A, Eichinger S, Lang I, Panzer S . Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J. 2009; 30(15):1831-6. DOI: 10.1093/eurheartj/ehp186. View

17.

Nierodzik M, Karpatkin S . Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006; 10(5):355-62. DOI: 10.1016/j.ccr.2006.10.002. View

18.

Reiter R, Derhaschnig U, Spiel A, Keen P, Cardona F, Mayr F . Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost. 2003; 90(5):898-903. DOI: 10.1160/TH03-04-0245. View

19.

Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel R . Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003; 89(6):1098-106. View

20.

Karpatkin S, Pearlstein E . Role of platelets in tumor cell metastases. Ann Intern Med. 1981; 95(5):636-41. DOI: 10.7326/0003-4819-95-5-636. View